Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika Announces Successful Completion of First Human Surgical Procedure with Injectable HA-Based Bone Repair Therapy
Company to Deploy Hybrid Commercial Strategy to Support U.S.Sales and Distribution BEDFORD, Mass. --(BUSINESS WIRE)--Aug. 13, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary
View HTML
Toggle Summary Anika Reports Second Quarter 2019 Financial Results
Delivers Strong Bottom Line Performance with $0.67 Diluted EPS CINGAL Revenue Drives International Viscosupplement Revenue Growth of 28% Year-over-Year Announces Decision to Advance CINGAL Program Towards U.S. Regulatory Approval Raises Full Year 2019 Revenue and Adjusted EBITDA Guidance BEDFORD,
View HTML
Toggle Summary Anika to Exhibit its HA-Based Bone Repair Therapy at the 2019 American Orthopaedic Society for Sports Medicine Annual Meeting
BEDFORD, Mass. --(BUSINESS WIRE)--Jul. 11, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to exhibit its injectable,
View HTML
Toggle Summary Anika to Issue Second-Quarter 2019 Financial Results and Business Highlights on Wednesday, July 24
BEDFORD, Mass. --(BUSINESS WIRE)--Jul. 10, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2019 financial results after the close of the market on Wednesday, July 24, 2019 and hold its investor conference call on the same day,
View HTML
Toggle Summary Anika Appoints James Loerop as Executive Vice President of Business Development and Strategic Planning
Industry veteran brings extensive experience leading business development groups BEDFORD, Mass. --(BUSINESS WIRE)--Jul. 8, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary
View HTML
Toggle Summary Anika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Cartilage Repair Scaffold at the 2019 International Cartilage Regeneration and Joint Preservation Society (ICRS) Focus Meeting
BEDFORD, Mass. --(BUSINESS WIRE)--Jun. 5, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase HYALOFAST, a
View HTML
Toggle Summary Anika to Showcase Regenerative Medicine and Orthobiologics Portfolio at the 12th Biennial International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine Congress
BEDFORD, Mass. --(BUSINESS WIRE)--May 13, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its regenerative
View HTML
Toggle Summary Anika to Participate in Two Investor Events in May 2019
BEDFORD, Mass. --(BUSINESS WIRE)--May 6, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that the Company will participate in
View HTML
Toggle Summary Anika Reports First Quarter 2019 Financial Results
Total Revenue Increased 16% Year-over-Year Solid Bottom Line Performance with $0.31 Diluted EPS New Leadership Added to Accelerate Innovation and Expand Commercial Reach Announces $50 Million Share Repurchase Program BEDFORD, Mass. --(BUSINESS WIRE)--May 2, 2019-- Anika Therapeutics, Inc.
View HTML
Toggle Summary Anika Announces $50 Million Share Repurchase Program
BEDFORD, Mass. --(BUSINESS WIRE)--May 2, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology , today announced that its Board of Directors has
View HTML